GlassScriptPhysician profile
Margot D Henderson
NPI 1023092822
$3,576.01
in general payments reported to CMS, 2019-2025
51 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $596 · 2023: $507 · 2024: $1,403 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.38 |
| Education | $217.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $261.24 | 2021-2025 | Xospata, Vyloy, Xtandi |
| Abbvie INC. | $188.37 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.97 | 2022-2025 | Enhertu |
| Genzyme Corporation | $166.95 | 2021-2024 | |
| Daiichi Sankyo INC. | $146.98 | 2024 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $145.12 | 2021-2025 | Carvykti, Tecvayli, Rybrevant |
| Emd Serono, INC. | $142.83 | 2021-2025 | |
| Incyte Corporation | $139.59 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Amgen INC. | $130.01 | 2022-2023 | Vectibix, Nplate, Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $126.06 | 2021-2023 | |
| Aveo Pharmaceuticals, INC. | $123.65 | 2023-2024 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $112.35 | 2022-2024 | Libtayo |
| Sobi, INC | $104.29 | 2024-2025 | |
| Beigene USA, INC. | $98.23 | 2022-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $94.80 | 2021-2024 | Opdivo |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.22 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $92.97 | 2021-2025 | Gavreto, Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $77.18 | 2024-2025 | Tivdak, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.95 | 2021-2022 | |
| Genentech USA, INC. | $71.90 | 2022-2024 | Venclexta, Polivy, Lunsumio |
| Novartis Pharmaceuticals Corporation | $67.48 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $65.00 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Pharmacosmos Therapeutics INC. | $60.26 | 2022-2024 | Monoferric |
| Gilead Sciences, INC. | $57.74 | 2021-2024 | |
| Pharmaessentia USA Corporation | $52.06 | 2024 | Besremi |
| Pfizer INC. | $49.74 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.67 | 2024 | Iclusig |
| Seagen INC. | $46.53 | 2022 | |
| Celgene Corporation | $42.39 | 2024 | Reblozyl, Pomalyst |
| Jazz Pharmaceuticals INC. | $39.09 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.91 | 2023-2025 | Ojjaara, Shingrix |
| Lilly USA, LLC | $35.32 | 2021-2024 | Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $33.50 | 2022-2023 | Imbruvica |
| Geron Corporation | $32.58 | 2024 | Rytelo |
| Progenics Pharmaceuticals, INC. | $28.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $27.24 | 2024 | Ultomiris |
| Amneal Pharmaceuticals LLC | $25.72 | 2024 | Avastin, Neupogen, Neulasta |
| Myovant Sciences INC. | $24.41 | 2021 | |
| Tersera Therapeutics LLC | $23.37 | 2025 | Xermelo |
| Celltrion USA INC. | $20.46 | 2024 | Vegzelma |
| Sandoz INC. | $20.22 | 2021 | |
| Blueprint Medicines Corporation | $19.77 | 2024 | Ayvakit |
| Tempus Ai, INC | $19.31 | 2024 | |
| Morphosys, US INC. | $18.43 | 2024 | Monjuvi |
| Sumitomo Pharma America, INC. | $18.33 | 2023 | Orgovyx |
| Adaptive Biotechnologies Corporation | $18.25 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.52 | 2025 | Onivyde |
| Exelixis INC. | $14.13 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.02 | 2023 | Truxima |
| Alnylam Pharmaceuticals INC. | $13.84 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margot Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.